Surrey researchers Sign in
A randomized placebo-controlled trial of saracatinib (AZD0530) plus weekly paclitaxel in platinum-resistant ovarian, fallopian-tube, or primary peritoneal cancer (SaPPrOC)
Conference presentation   Peer reviewed

A randomized placebo-controlled trial of saracatinib (AZD0530) plus weekly paclitaxel in platinum-resistant ovarian, fallopian-tube, or primary peritoneal cancer (SaPPrOC)

IA McNeish, JA Ledermann, LC Webber, LE James, SB Kaye, GJS Rustin, G Hall, A Clamp, HM Earl, SN Banerjee, …
JOURNAL OF CLINICAL ONCOLOGY, Vol.31(15)
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) (Chicago, IL, 31/05/2013 - 04/06/2013)
20/05/2013

Abstract

Science & Technology Life Sciences & Biomedicine Oncology ONCOLOGY
url
http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000335419602028&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=11d2a86992e85fb529977dad66a846d5View
Author

Metrics

29 Record Views

Details

Usage Policy